Germany’s Merck KGaA said it is in advanced talks for a potential acquisition of SpringWorks Therapeutics, a U.S. biopharmaceutical company that specializes in rare diseases and cancer.

Barclays maintained an 'Overweight' rating on SpringWorks, with a price target of $63. It sees limited regulatory risk to a potential Merck buyout. Retail traders on Stocktwits reacted strongly to ...

German chemical and pharma group Merck KGaA has acknowledged that it is in talks to buy US biotech SpringWorks, but cautioned there is no guarantee a deal will be forthcoming. Merck said in a ...

Hard on the heels of the disclosure that Merck KGaA is talking to SpringWorks about a possible takeover, a new FDA approval could have sweetened the deal. Stamford, Connecticut-based SpringWorks ...

Merck KGaA reaffirmed its strong performance in the healthcare sector in its FY 2024 earnings report, but provided little additional information on ongoing acquisition talks with SpringWorks ...

Lekha Gupta Germany's Merck In Talks To Buy Cancer Drug Maker SpringWorks Therapeutics Merck KGaA is in advanced talks to acquire SpringWorks, whose portfolio could bolster Merck's oncology ...

One of the most significant developments for SpringWorks is the ongoing merger and acquisition discussions with Merck KGaA. Analysts view this potential acquisition as strategically sound for several ...

February 11, 2025 Germany's Merck in advanced talks to acquire US biotech firm SpringWorks Merck KGaA , the German healthcare and technology group, said on Monday it is in advanced talks to ...

Lekha Gupta Germany's Merck In Talks To Buy Cancer Drug Maker SpringWorks Therapeutics Merck KGaA is in advanced talks to acquire SpringWorks, whose portfolio could bolster Merck's oncology ...